KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $15.4 million.

  • Acadia Pharmaceuticals' Other Accumulated Expenses fell 60.70% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 60.70%. This contributed to the annual value of $15.4 million for FY2024, which is 39.57% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Other Accumulated Expenses is $15.4 million, which was up 39.57% from $11.0 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Other Accumulated Expenses registered a high of $15.4 million during FY2024, and its lowest value of $2.7 million during FY2021.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $11.0 million (2023), whereas its average is $9.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 47.46% in 2021, then surged by 307.53% in 2023.
  • Acadia Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $5.1 million in 2020, then plummeted by 47.46% to $2.7 million in 2021, then rose by 0.82% to $2.7 million in 2022, then spiked by 307.53% to $11.0 million in 2023, then skyrocketed by 39.57% to $15.4 million in 2024.